Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms JUVE-BALM
- Sponsors Eli Lilly and Company
- 11 Sep 2023 Planned End Date changed from 7 Aug 2023 to 27 Oct 2025.
- 11 Sep 2023 Planned primary completion date changed from 7 Aug 2023 to 27 Oct 2025.
- 21 Aug 2023 This trial has been discontinued in Denmark, according to European Clinical Trials Database record.